RxDoctor Payments DataLook up a doctor →

Thomas Waggoner, DO

Interventional Cardiology · Tucson, AZNPI 1891083812

Payments from drug & device makers

$4,072,732in general payments, 2019–2025

Across 2,032 payments — averaging $2004.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$3M
  • Abbott$395K
  • Edwards Lifesciences$375K
  • Shockwave Medical, Inc$64K
  • Philips North America LLC$56K
  • Abiomed$55K
  • plus $124K from 34 others
$263in research payments, 2019–2025

Across 3 payments — averaging $87.71 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Abiomed$263

What the payments were for

  • Consulting fees$250,48141%
  • Speaking & faculty fees$230,65637%
  • Travel & lodging$84,40314%
  • Food & beverage$51,3738%
  • Education$320%
  • Gifts$250%
  • Other$660%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,072,732 in reported general payments places this provider in the 95th percentile of 223 interventional cardiology providers in Arizona.

See all interventional cardiology providers in Arizona

Medicare billing

Part B allowed, 2024
$527,829
Medicare patients
769
Services billed
7,931

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban150$205,816
EntrestoSacubitril/Valsartan31$34,139
Repatha SureclickEvolocumab28$22,730
JardianceEmpagliflozin13$19,103
Enoxaparin Sodium11$2,486
ClopidogrelClopidogrel Bisulfate146$2,124
Atorvastatin Calcium161$1,512
Metoprolol Succinate114$1,223
Losartan Potassium107$1,041
Flecainide Acetate21$1,000
Carvedilol131$950
Midodrine Hcl11$942
Valsartan11$882
Rosuvastatin Calcium51$806
Metoprolol Tartrate102$793

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$79$205,816150 claims
NovartisEntresto$119$34,13931 claims
Boehringer IngelheimJardiance$14$19,10313 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 223 interventional cardiology providers in Arizona.

Other interventional cardiology in Tucson

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →